Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.

摘要: Aim Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) are well established in treating metastatic pulmonary adenocarcinoma, especially patients with activating EGFR mutations. mutations rare squamous cell carcinomas (SCCs). There conflicting data supporting efficacy of EGFR-TKIs advanced lung SCC. We analyzed impact on progression-free survival (PFS) and overall (OS) unselected SCC. Methods We searched for randomized controlled trials (RCTs) comparing alone placebo non-small cancer. RCTs all settings (front line/maintenance/subsequent) were included. The primary outcome was OS SCC population. used published hazard ratios (HRs), when unavailable, unpublished sought. Pooled estimates treatment effect PFS calculated using fixed-effects inverse variance weighted method. Results Eight eligible included: 2 first-line, 6 second-line or beyond, evaluating 1781 patients. Data available four studies (second-line; N = 1420) (3 second-line, 1 first-line; N = 788). significantly prolonged a HR 0.88 (95% confidence interval [CI] 0.78–1.00, P = 0.04), 0.77 CI 0.65–0.92, P = 0.004). Conclusion EGFR However, have modest therapeutic compared to SCC, can be considered these EGFR-mutation-independent mechanisms may explain this setting.